atai shares jump 10% on positive trial data for depression nasal spray
Shares in atai Life Sciences (NASDAQ:ATAI, ETR:9VC) rose 10% on Tuesday after the company and its UK partner Beckley Psytech reported encouraging mid-stage trial results for their experimental nasal spray treatment for depression. The therapy, BPL-003, is a formulation of mebufotenin benzoate delivered via nasal spray.
atai Life Sciences and Beckley Psytech report positive mid-stage trial results for depression treatment
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech said Tuesday that their experimental nasal spray for depression showed promising results in a mid-stage clinical trial, bolstering hopes for a new treatment option in an area where existing therapies often fall short. The drug, known as BPL-003, is a formulation of mebufotenin benzoate delivered through a nasal spray.
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
atai Life Sciences marks milestone quarter with key clinical wins, Beckley merger plans
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has reflected on a “transformational” first half of 2025, marked by a series of clinical and corporate milestones, including positive topline data from its Phase 2b trial of BPL-003 for treatment-resistant depression. The randomized, quadruple-masked global study enrolled 193 patients and met its primary and all key secondary endpoints.
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus
Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed strong phase 2b results, with rapid and sustained efficacy, and could be phase 2 program with FDA allowance. The pending merger with Beckley Psytech and upcoming catalysts, including FDA meetings and OLE study data, offer significant upside potential.
atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a Phase 2b trial of inidascamine in cognitive impairment associated with schizophrenia (CIAS), which did not meet the primary endpoint but demonstrated consistent signs of cognitive and functional benefit and maintained a favorable safety profile. The double-blind, placebo-controlled study enrolled 242 patients and tested two doses of inidascamine over a six-week treatment period.
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferies believe. BPL-003, an intranasal formulation of DMT developed in partnership in Beckley Psytech, demonstrated rapid, robust and durable antidepressant effects with a single dose.
Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing treatment paradigms, potentially rivaling J&J's Spravato if regulatory hurdles are cleared. Regulatory approval remains uncertain due to controlled substance scheduling, but Atai's differentiated pipeline and patent position offer significant long-term upside.
Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proceeds of $50 million. The clincial study, in partnership with Beckley Psytech, is evaluating BPL-003, a formulation of the psychedelic compound mebufotenin, also known as DMT, that is administered using a nasal spray.
